Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1068 | 966 | 1086 | 1189 | 1604 | 2629 |
Fund Return | 6.85% | -3.43% | 8.6% | 5.95% | 9.91% | 10.15% |
Place in category | 360 | 822 | 465 | 102 | 62 | 99 |
% in Category | 37 | 85 | 47 | 19 | 11 | 31 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
AXA Framlington Global Technology a | 1.27B | 4.69 | 2.44 | 18.31 | ||
AXA Framlington Global Technology F | 1.27B | 4.70 | 2.45 | 18.31 | ||
GB00B5LXGG05 | 1.17B | 10.37 | 7.15 | 16.02 | ||
AXA Framlington UK Mid Cap Fund S A | 264.56M | -1.31 | -3.04 | 4.43 | ||
AXA Framlington UK Mid Cap Fund S I | 264.56M | -1.30 | -3.05 | 4.46 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Janus Global Life Sciences Fund U G | 3.98B | 10.92 | 7.98 | 12.62 | ||
Wellington Global Health Care EquiG | 2.12B | 5.25 | 5.27 | 13.12 | ||
Global Health Care Fund W Acc GBP | 110.49M | 8.57 | 4.09 | 10.65 | ||
Adamant Medtech I GBP | 1.57B | 8.97 | 1.03 | 12.78 | ||
Pharmaceuticals Index Trust F Acc | 256.85K | 8.57 | 5.66 | 10.62 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Eli Lilly | US5324571083 | 8.91 | 749.92 | -0.46% | |
Novo Nordisk B | DK0062498333 | 7.38 | 721.8 | -2.21% | |
UnitedHealth | US91324P1021 | 6.91 | 597.49 | -0.50% | |
Merck&Co | US58933Y1055 | 4.71 | 99.86 | +2.48% | |
AstraZeneca | GB0009895292 | 4.52 | 10,062.0 | +0.93% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Sell | Sell | Buy |
Technical Indicators | Strong Sell | Strong Sell | Neutral |
Summary | Strong Sell | Strong Sell | Neutral |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review